Skip to content

Simulations Plus SLP Development — Revenue

Similar metrics at other companies

Ondas, Inc.
 logo
ONDSDevelopment Revenue — Revenue
$2.43M+1,031%
FRP Holdings logo
FRPHDevelopment — Revenues:
$482K+60.1%
nLIGHT, Inc. logo
LASRDevelopment — Total Revenue
$21.98M+37.5%
GRAIL, Inc. logo
GRALDevelopment Services — Total Revenue
$953K-64.8%
Ondas, Inc.
 logo
ONDSDevelopment Revenue — Revenue (Gross)
$2.43M+1,031%
Arcus Biosciences logo
RCUSLicense and development services — Total revenues
$12M-40.0%

Other financials

Income statement

See full
Revenue$24.3M+8.3%
Gross profit$16.1M+23.0%
Operating income$5.6M+108%
Net income$4.5M+47.5%
EPS (diluted)$0.22+46.7%

Balance sheet

See full
Cash & equivalents$25.7M+134%
Total debt$508.0K-36.2%
Total equity$133.8M-29.4%
Total assets$146.5M-27.3%

Cash flow

See full
Operating cash flow$6.4M+13.1%
CapEx$46.0K-30.3%
Free cash flow$6.4M+13.6%

Valuation

See full
Market cap$366.73M+5.2%
Enterprise value$341.51M+6.0%
P/S4.6×+0.2×

Profitability

See full
Gross margin62%+6.7pp
Operating margin-84.3%
Net margin-78%-87.2pp
FCF margin29.5%+14.9pp

Returns & leverage

See full
Return on equity-38.8%-42.8pp
Debt / equity0.0×
Current ratio5.5×+1.1×

Where this comes from

Reported directly by Simulations Plus in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Simulations Plus’s 10-Q, filed April 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Simulations Plus's development — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Simulations Plus's development — revenue?
Simulations Plus (SLP) reported development — revenue of $18.86M in Q4 2025.
What does development — revenue mean?
This metric represents the total gross revenue generated from the development segment, which encompasses specialized software solutions and associated consulting services for pharmaceutical research. It serves as a primary indicator of the company's ability to monetize its intellectual property and technical expertise within the drug discovery and development lifecycle. Tracking this revenue stream helps investors assess the scale and growth trajectory of the core business offerings.